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Inclusion criteria 
Studies:  
Randomized controlled trials. 
Participants: 
People with clinically diagnosed tuberculous 
meningitis. 
Intervention: 
Intervention: corticosteroids plus antituberculous 
treatment. 
Control: antituberculous treatment with or without 
placebo.   
Outcomes: 
Primary: death, death or disabling residual deficit at 
the end of follow up. 
Adverse events: any adverse event. 
Results 
• Seven trials with 1140 participants were included; 
allocation concealment was adequate in one trial. 
Five trials assessed dexamethasone and two 
assessed prednisolone. Only one trial included HIV
-positive participants. 
• There were fewer deaths in participants treated 
with corticosteroids (relative risk 0.78, 95% 
confidence interval 0.67 to 0.91; 1140 participants, 
7 trials). The effect was significant in participants 
with mild, moderately severe, or severe illness. 
• The risk of death or disabling residual neurological 
deficit was reduced with corticosteroids (relative 
risk 0.82, 95% confidence interval 0.70 to 0.97; 
720 participants, 3 trials). 
• One trial stratified the results for death and death or 
disabling residual deficit by HIV status. The trial did 
not detect any difference in the effect of 
corticosteroids between the groups; however, the 
number of HIV-positive participants included was 
very small (n = 98). 
• Five trials mentioned adverse events, and two 
reported incidence. Adverse events included 
gastrointestinal bleeding, bacterial and fungal 
infections, and hyperglycaemia; the number of 
events in participants receiving corticosteroids were 
no more than in the control groups. 
Are corticosteroid drugs effective in people with  
tuberculous meningitis? 
Corticosteroids reduce deaths in HIV-negative patients on 
treatment for tuberculous meningitis. 
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Authors’ conclusions 
Implications for practice:  
For HIV-negative people who are being treated for tuberculous meningitis, corticosteroids reduce the risk of 
death and of disabling residual neurological deficit. There is not enough evidence to assess whether 
corticosteroids benefit people who are HIV positive.  
Implications for research: 
New randomized controlled trials are needed to assess the relative effectiveness of different corticosteroids, and 
the optimum duration of corticosteroid treatment. Trials are also needed to assess the effect of corticosteroid 
treatment for HIV-positive people with tuberculous meningitis.  
The Cochrane Database of Systematic Reviews is available from www.wiley.com, and free for eligible countries through www.healthinternetwork.org.  
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